Low dose alnodesertib plus gemcitabine met the primary endpoint of progression-free survival (PFS) versus gemcitabine alone in patients with platinum-resistant high-grade serous ovarian cancerStudy ...
In this video, Rebecca Stone, MD, MS, discussed the need for improved prevention and screening methods for ovarian cancer.
The Oxford-based biotechnology company Theolytics has been awarded €8 million in non-dilutive grant funding from Horizon ...
A new study published in the Journal of the American Medical Association revealed that the chance of developing serous ovarian cancer was shown to be reduced by almost 80% when ...
Memorial Sloan Kettering Cancer Center investigators and collaborators have tested rezatapopt, an oral p53 reactivator ...
Fallopian tube cancer, a rare gynecologic cancer, is gaining awareness due to its potential origin for many high-grade serous ovarian cancers. New diagnostics improve early detection and treatment, ...
NEW YORK, Feb. 19, 2026 /PRNewswire/ -- The Global Ovarian Cancer Research Consortium awarded its inaugural AI Accelerator Grant to an international research team studying whether artificial ...
Pending final negotiation, grant will fund up to 20 patients in the OCTOPOD-IV Phase 2a expansion study of THEO-260 in platinum-resistant ovarian cancerCompetitive funding award highlights Theolytics’ ...
CNW/ - The Global Ovarian Cancer Research Consortium, of which Ovarian Cancer Canada is a founding member, has awarded its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results